Ultima-Ultrazompic at a Glance
Ultima-Ultrazompic 5 mg is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Ultima Peptides for advanced metabolic research applications. This research-grade semaglutide formulation enables investigators to study GLP-1 pathway modulation and incretin hormone mechanisms in controlled laboratory environments. Researchers examining metabolic regulation pathways can investigate this compound’s interaction with GLP-1 receptors across various experimental models. Laboratory studies have demonstrated semaglutide’s mechanism involves binding to GLP-1 receptors, subsequently activating intracellular signalling cascades that influence glucose homeostasis and metabolic function. Scientists at Stroid UK Shop supply this compound exclusively for in-vitro research purposes.
Laboratory Research Applications
This peptide enables comprehensive investigation of incretin hormone pathways and glucose-dependent insulin secretion mechanisms. Research teams can examine how GLP-1 receptor activation influences pancreatic beta-cell function and glucagon suppression in experimental settings. Studies investigating gastric emptying regulation and appetite control pathways frequently utilise this compound to understand incretin-based metabolic signalling. Advanced research protocols examine semaglutide’s effects on glucose transporter expression and hepatic glucose production in cellular models. Investigators studying metabolic modulators can analyse this compound’s interaction with GLP-1 receptor subtypes and downstream signalling pathways. Research applications include studying incretin hormone stability, receptor binding kinetics, and cellular response mechanisms. Laboratory protocols examining metabolic dysfunction models utilise this peptide to investigate GLP-1 pathway restoration and metabolic regulation. Scientists can evaluate compound stability, bioactivity maintenance, and receptor selectivity across different experimental conditions. Teams researching selective modulators and research peptides can compare semaglutide’s mechanisms with other metabolic pathway modulators.
Technical Specifications
| Active Compound | Semaglutide |
|---|---|
| Concentration | 5 mg per vial |
| Manufacturer | Ultima Peptides |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 g/mol |
| Storage Requirements | -20°C lyophilised, 2-8°C reconstituted |
| Stability | 36 months unopened, 30 days reconstituted |
| Research Grade | Laboratory analytical standard |
Research Compliance Statement
Ultima-Ultrazompic 5 mg is manufactured exclusively for in-vitro laboratory research and analytical applications. This product is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must maintain appropriate laboratory protocols and safety measures when handling this compound. All studies should be conducted within accredited research facilities by qualified scientific personnel. This peptide requires proper storage conditions and handling procedures to maintain research-grade quality and analytical integrity.
